Test antibodies plus or minus chemo for advanced head and neck cancer
Part of Cancer clinical trials.
This early-phase study tests a combination of antibody medicines (with optional chemotherapy) in people with advanced or metastatic head and neck squamous cell carcinoma. The goal is to see how well the treatment controls the cancer and what side effects are like.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (18–75) and can be expected to live at least 3 more months
- Your cancer is confirmed as head and neck squamous cell cancer in the mouth, throat, or voice box
- You can provide stored or new tumor tissue samples from the main tumor or a metastasis
- You have at least one measurable tumor spot on scan, and your overall strength is good (ECOG 0–1)
- Your body and organ tests (blood, kidneys, liver, clotting, urine protein) must be within required limits
- Your heart function is ok (left heart pumping, LVEF at least 50%) and you’re not on certain medicines that interfere
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an immunotherapy drug (toripalimab) with or without another targeted drug (cetuximab) to standard chemotherapy before surgery can improve outcomes for people with advanced head and neck squamous cell carcinoma that can be removed with surgery.
This trial tests a combination of two immunotherapy drugs (IBI110 and sintilimab) with chemotherapy before surgery for people with advanced head and neck cancer that can be removed surgically. The goal is to see if this approach helps shrink tumors and improve outcomes.
This trial tests a combination of immunotherapy (tirilizumab) and two chemotherapy drugs (albumin-bound paclitaxel and cisplatin) for people with advanced but removable oral cancer. The goal is to see if this treatment shrinks the tumor before surgery and improves outcomes.
This trial tests two new drugs, BL-B01D1 and SI-B003, alone or together, for people with head and neck squamous cell carcinoma that has come back or spread. It may also include other solid tumors. The goal is to see if these drugs can shrink tumors or slow their growth.
This trial tests a combination of an immunotherapy drug (sintilimab) with radiation and chemotherapy for people with advanced head and neck cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This Phase 2 study tests whether tislelizumab (an immunotherapy) combined with chemotherapy works better for locally advanced head and neck squamous cell cancer. It aims to improve cancer control when the tumor is large and has not spread to distant organs.
Hear when a new Squamous Cell Carcinoma of Head and Neck trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.